Grail is a company dedicated to detecting early cancer. They have developed Galleri which is the first-of-its-kind test that uses a single blood test to look for a signal shared by more than 50 types of cancer.
Cancer is a leading cause of death for life insurance policyholders, with about 50% of death claims resulting from cancer.
Statistics say one in two men will be diagnosed with cancer in their lifetime, and one in three women and one in five people are going to die from cancer. And your risk of cancer is 13 times greater if you’re over 50. That's a greater risk than if you had been a career smoker, or were medically obese, or had family history of cancer.
Although cancer screenings such as mammography or colonoscopy have been available for decades, those screenings are available for only five types of cancer – breast, uterine/cervical, prostate, lung and colorectal.
Those five cancers represent only about 30% of cancer deaths. The remaining 70% of cancer deaths are from cancers for which there’s no screening. They’re found in the late stages where there is no treatment. When cancer is found early, the survival rate is much higher with some estimates being as high as 89% as opposed to 21% when found in the late stages.
Grail’s Galleri test screens for multiple cancers at once. Being able detect cancer before it metastasizes, we can now extend an individuals lifespan.
Now life insurance customers with John Hancock Life Insurance who are participating in the John Hancock Vitality program have access to Grail's Galleri multi-cancer early detection test.
To learn more about John Hancock products and the Galleri test, reach out to me to schedule a consultation.
Comments